Docoh
Loading...

LFVN Lifevantage

LifeVantage Corporation is a pioneer in Nutrigenomics - a new science dedicated to biohacking the human aging code. The Company engages in the identification, research, development and distribution of advanced nutraceutical dietary supplements and skin and hair care products, including its Protandim® product line, LifeVantage® Omega+ and ProBio dietary supplements, the TrueScience® line of Nrf2 infused skin care and hair care products, Petandim® for Dogs, Axio® smart energy drink mixes, and the PhysIQ™ weight management system. LifeVantage was founded in 2003 and is headquartered in Salt Lake City, Utah.

Company profile

Ticker
LFVN
Exchange
CEO
Steven R. Fife
Employees
Incorporated
Location
Fiscal year end
Former names
LIFELINE THERAPEUTICS, INC., YAAK RIVER RESOURCES INC
SEC CIK
IRS number
841097796

LFVN stock data

(
)

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

29 Apr 21
24 Jun 21
30 Jun 21
Quarter (USD)
Mar 21 Dec 20 Sep 20 Jun 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Jun 20 Jun 19 Jun 18 Jun 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from Lifevantage earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 18.96M 18.96M 18.96M 18.96M 18.96M 18.96M
Cash burn (monthly) 257K (positive/no burn) (positive/no burn) (positive/no burn) (positive/no burn) (positive/no burn)
Cash used (since last report) 716.5K n/a n/a n/a n/a n/a
Cash remaining 18.24M n/a n/a n/a n/a n/a
Runway (months of cash) 71.0 n/a n/a n/a n/a n/a

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
1 Apr 21 McMurray Kevin Common Stock Payment of exercise Dispose F No No 9.44 1,030 9.72K 49,870
1 Apr 21 McMurray Kevin Common Stock Option exercise Aquire M No No 0 194 0 50,900
1 Apr 21 McMurray Kevin Common Stock Option exercise Aquire M No No 0 981 0 50,706
1 Apr 21 McMurray Kevin Performance Stock Units Common Stock Option exercise Dispose M No No 0 194 0 0
1 Apr 21 McMurray Kevin Performance Stock Units Common Stock Option exercise Dispose M No No 0 981 0 0
1 Apr 21 Rose Justin Common Stock Payment of exercise Dispose F No No 9.44 1,288 12.16K 153,552
1 Apr 21 Rose Justin Common Stock Option exercise Aquire M No No 0 215 0 154,840
1 Apr 21 Rose Justin Common Stock Option exercise Aquire M No No 0 1,178 0 154,625
1 Apr 21 Rose Justin Performance Stock Units Common Stock Option exercise Dispose M No No 0 215 0 1,075
1 Apr 21 Rose Justin Performance Stock Units Common Stock Option exercise Dispose M No No 0 1,178 0 1,177

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

49.9% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 81 88 -8.0%
Opened positions 10 14 -28.6%
Closed positions 17 14 +21.4%
Increased positions 30 29 +3.4%
Reduced positions 25 26 -3.8%
13F shares
Current Prev Q Change
Total value 101.81M 89.25M +14.1%
Total shares 6.99M 7.06M -1.1%
Total puts 0 0
Total calls 0 0
Total put/call ratio
Largest owners
Shares Value Change
Renaissance Technologies 1.21M $11.32M -3.1%
Vanguard 1.03M $9.61M -12.1%
BLK Blackrock 1.01M $9.43M +7.6%
Acadian Asset Management 397.46K $3.72M -25.3%
MS Morgan Stanley 343.43K $3.21M +43.2%
Dimensional Fund Advisors 316.93K $2.98M -11.3%
STT State Street 245.84K $2.3M -7.1%
DB Deutsche Bank AG - Registered Shares 234.54K $2.19M +71.9%
Geode Capital Management 207.81K $1.94M +0.7%
Los Angeles Capital Management & Equity Research 183.98K $1.72M +8.6%
Largest transactions
Shares Bought/sold Change
Vanguard 1.03M -141.54K -12.1%
Acadian Asset Management 397.46K -134.42K -25.3%
WFC Wells Fargo & Co. 161.05K +118.16K +275.5%
MS Morgan Stanley 343.43K +103.63K +43.2%
Arrowstreet Capital, Limited Partnership 0 -101.41K EXIT
DB Deutsche Bank AG - Registered Shares 234.54K +98.08K +71.9%
BLK Blackrock 1.01M +71.52K +7.6%
Dimensional Fund Advisors 316.93K -40.32K -11.3%
Renaissance Technologies 1.21M -38.89K -3.1%
Charles Schwab Investment Management 28.11K -33.99K -54.7%

Financial report summary

?
Management Discussion
  • Revenue. We generated net revenue of $51.6 million and $56.1 million during the three months ended March 31, 2021 and 2020, respectively. We generated net revenue of $165.4 million and $173.5 million during the nine months ended March 31, 2021 and 2020, respectively. Foreign currency fluctuations positively impacted our revenue $0.9 million or 1.6% and $1.8 million or 1.0% during the three and nine months ended March 31, 2021, respectively.
  • Revenue in the Americas region for the three and nine months ended March 31, 2021 decreased $3.8 million or 9.4% and $7.7 million or 6.2%, respectively, from the prior year periods. Total Active Accounts decreased by 6.2% in the region compared to the prior year period which drove the decrease in revenue. Additionally, during our prior year October 2019 global convention, we launched our Protandim® NAD Synergizer™ product which generated significant revenue during the prior year periods. The decrease in revenue for the three months ended March 31, 2021 relative to the prior year period was partially offset by encouraging initial sales of our new LifeVantage® Daily Wellness product which we launched during the three months ended March 31, 2021 and our virtual Elite Academy held in March 2021. The decrease in revenue for the nine months ended March 31, 2021 relative to the prior year period was partially offset by revenue generated from the expansion of our Axio® drink mix line up with the launch of new, limited-time only flavors during our October 2020 virtual convention, as well as increased average revenue per account as compared to the prior year periods and increased sales associated with various product promotions during our second fiscal quarter.
  • Revenue in the Asia/Pacific & Europe region decreased $0.7 million or 4.7% and $0.5 million or 1.0% for the three and nine months ended March 31, 2021, respectively, as compared to the prior year periods. Active Accounts in the region increased 2.2% compared to the prior year period. Japan revenues, on a full year over year basis, are down slightly, due to continued restrictions in place for in person meetings and recruiting due to the COVID-19 pandemic. We continue to be encouraged by the results we are seeing in our Australia and New Zealand region following the full on the ground launch of New Zealand in November 2019. We continue to experience weakening in our Greater China market in the current year period and are seeing decreases in both our Thailand and European markets as well.
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Avg
New words: Alissa, attached, Bancorporation, Bank, copy, Counsel, covenant, Daily, dba, description, entirety, European, Exhibit, expansion, floor, foregoing, hereto, hired, Kevin, McMurray, Neufeld, recognition, text, trip
Removed: consistent, UT